lopinavir-ritonavir
Selected indexed studies
- Lopinavir-ritonavir for COVID-19: A living systematic review. (Medwave, 2020) [PMID:32678815]
- Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. (Cardiovasc Drugs Ther, 2021) [PMID:32918656]
- BET 1: Lopinavir-ritonavir and COVID-19. (Emerg Med J, 2020) [PMID:32616658]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis. (2020) pubmed
- Lopinavir-ritonavir for COVID-19: A living systematic review. (2020) pubmed
- Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. (2021) pubmed
- BET 1: Lopinavir-ritonavir and COVID-19. (2020) pubmed
- Anti-HIV drugs lopinavir/ritonavir activate bitter taste receptors. (2023) pubmed
- Monotherapy with lopinavir/ritonavir. (2007) pubmed
- Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019. (2022) pubmed
- Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients. (2021) pubmed
- A Trial of Lopinavir-Ritonavir in Covid-19. (2020) pubmed
- A Trial of Lopinavir-Ritonavir in Covid-19. (2020) pubmed